Age-Less Energy: The Real Science of SS-31 | Age-Less Top 20 Peptides
About this episode
Dr. Ethan discusses the FDA approval and implications of SS-31, a novel mitochondria-targeted therapy.
SS-31 — also known as elamipretide — occupies a category no other compound in this series can claim: it is the first mitochondria-targeted therapy ever to receive FDA approval. In this episode, Dr. Ethan traces the compound from its accidental discovery in a Weill Cornell pharmacology lab through to its September 2025 accelerated approval for Barth syndrome, unpacking the biology of cardiolipin — the inner mitochondrial membrane phospholipid whose decline with age sits at the centre of SS-31's entire mechanistic rationale — and explaining precisely why a peptide that concentrates over 1,000-fold inside the mitochondrial membrane represents a genuinely novel class of therapeutic tool. The mechanism is well-supported, the preclinical literature is large and independently replicated, and the clinical trial programme is the most rigorous of any compound covered in this series so far. The honest picture is more nuanced than the approval alone would suggest. The regulatory journey was long and difficult — an initial refusal to file, a subsequent rejection, and an eventual accelerated approval based on an intermediate endpoint in a rare paediatric disease population. The heart failure…
More episodes of The Science of Age-less Living
- Age-less or Overhyped? The Sixty-Year Cerebrolysin Puzzle | The Age-Less Top 20 Peptides
- Age-less by Design: Inside the Cell's Peptide Factory
- Age-Less LL-37: The Antibiotic in Your Blood | The Age-Less Top 20 Peptides
- Age-Less Protection: The Real Science of Humanin | The Age-Less Top 20 Peptides
- Age-Less Cognition: The Real Science of Pinealon | Age-Less Top 20 Peptides
- Age-Less Cognition: The Real Science of SEMAX | Age-Less Top 20 Peptides
Explore listener stats, chart rankings, contacts and more on the The Science of Age-less Living podcast page.